{
    "root": "6718ba93-2693-44ba-93d2-8f873484a795",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "ODEFSEY",
    "value": "20250224",
    "ingredients": [
        {
            "name": "EMTRICITABINE",
            "code": "G70B4ETF4S",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31536"
        },
        {
            "name": "RILPIVIRINE HYDROCHLORIDE",
            "code": "212WAX8KDD",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_68602"
        },
        {
            "name": "TENOFOVIR ALAFENAMIDE FUMARATE",
            "code": "FWF6Q91TZO",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_90923"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "POLYSORBATE 20",
            "code": "7T1F30V5YH",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53424"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        }
    ],
    "indications": {
        "text": "odefsey indicated complete regimen treatment hiv-1 infection adult pediatric patients weighing least 25 kg : initial therapy antiretroviral treatment history hiv-1 rna less equal 100,000 copies/ml replace stable antiretroviral regimen virologically-suppressed ( hiv-1 rna less 50 copies/ml ) least 6 months history treatment failure known substitutions associated resistance individual components odefsey [ microbiology ( 12.4 ) ( 14 ) ] .",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "hiv-1 infection",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_324632"
            }
        ]
    },
    "contraindications": {
        "text": "testing : prior initiating odefsey , test hepatitis b virus infection . prior initiating odefsey , treatment clinically appropriate schedule , assess serum creatinine , estimated creatinine clearance , urine glucose , urine protein patients . patients chronic kidney disease , also assess serum phosphorus ( 2.1 ) recommended : one tablet taken orally daily meal . ( 2.2 ) pregnant patients already odefsey prior pregnancy virologically suppressed ( hiv-1 rna less 50 copies per ml ) , one tablet taken daily may continued . lower exposures rilpivirine observed pregnancy , therefore viral load monitored closely . ( 2.3 ) renal impairment : odefsey recommended patients estimated creatinine clearance 15 30 ml per minute , 15 ml per minute receiving chronic hemodialysis . ( 2.4 )",
        "doid_entities": [
            {
                "text": "hepatitis (DOID:2237)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2237"
            },
            {
                "text": "hepatitis b (DOID:2043)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2043"
            },
            {
                "text": "virus infection (DOID:934)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_934"
            },
            {
                "text": "chronic kidney disease (DOID:784)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_784"
            },
            {
                "text": "kidney disease (DOID:557)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_557"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "chronic kidney disease",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_133"
            }
        ]
    },
    "warningsAndPrecautions": "odefsey tablets gray , capsule-shaped , film coated `` gsi `` debossed one side `` 255 `` side . bottle contains 30 tablets ( ndc 61958-2101-1 ) , silica gel desiccant , polyester coil , closed child-resistant closure .",
    "adverseReactions": "odefsey contraindicated coadministered following drugs ; coadministration may result loss virologic response possible resistance odefsey class nnrtis [ ( 5.6 ) , ( 7 ) pharmacology ( 12.3 ) ] : anticonvulsants : carbamazepine , oxcarbazepine , phenobarbital , phenytoin antimycobacterials : rifampin , rifapentine glucocorticoid ( systemic ) : dexamethasone ( single-dose ) herbal products : st. john 's wort ( hypericum perforatum ) proton pump inhibitors : e.g . , dexlansoprazole , esomeprazole , lansoprazole , omeprazole , pantoprazole , rabeprazole",
    "indications_original": "ODEFSEY is indicated as a complete regimen for the treatment of HIV-1 infection in adult and pediatric patients weighing at least 25 kg:\n                  \n                  \n                     as initial therapy in those with no antiretroviral treatment history with HIV-1 RNA less than or equal to 100,000 copies/mL or\n                     to replace a stable antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies/mL) for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of ODEFSEY [see Microbiology (12.4) and Clinical Studies (14)].",
    "contraindications_original": "Testing: Prior to or when initiating ODEFSEY, test for hepatitis B virus infection. Prior to or when initiating ODEFSEY, and during treatment on a clinically appropriate schedule, assess serum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus ( 2.1 ) Recommended dosage: one tablet taken orally once daily with a meal. ( 2.2 ) For pregnant patients who are already on ODEFSEY prior to pregnancy and who are virologically suppressed (HIV-1 RNA less than 50 copies per mL), one tablet taken once daily may be continued. Lower exposures of rilpivirine were observed during pregnancy, therefore viral load should be monitored closely. ( 2.3 ) Renal impairment: ODEFSEY is not recommended in patients with estimated creatinine clearance of 15 to below 30 mL per minute, or below 15 mL per minute who are not receiving chronic hemodialysis. ( 2.4 )",
    "warningsAndPrecautions_original": "ODEFSEY tablets are gray, capsule-shaped, and film coated with \"GSI\" debossed on one side and \"255\" on the other side. Each bottle contains 30 tablets (NDC 61958-2101-1), a silica gel desiccant, and a polyester coil, and is closed with a child-resistant closure.",
    "adverseReactions_original": "ODEFSEY is contraindicated when coadministered with the following drugs; coadministration may result in loss of virologic response and possible resistance to ODEFSEY or to the class of NNRTIs [see Warnings and Precautions (5.6), Drug Interactions (7) and Clinical Pharmacology (12.3)]:\n                  \n                  \n                     Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital, phenytoin\n                     Antimycobacterials: rifampin, rifapentine\n                     Glucocorticoid (systemic): dexamethasone (more than a single-dose)\n                     Herbal Products: St. John's wort (Hypericum perforatum)\n                     \n                     Proton Pump Inhibitors: e.g., dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole",
    "drug": [
        {
            "name": "ODEFSEY",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_133010"
        }
    ]
}